Lexicon Pharmaceuticals (LXRX) Research & Development (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Research & Development for 17 consecutive years, with $12.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 16.64% year-over-year to $12.8 million; the TTM figure through Mar 2026 stood at $58.6 million (down 31.42% YoY), while the FY2025 annual figure was $61.1 million, down 27.65% from the prior year.
• Research & Development rose to $12.8 million in Q1 2026 per LXRX's latest filing, from $11.3 million in the prior quarter.
• Across five years, Research & Development topped out at $26.7 million in Q4 2024 and bottomed at $10.6 million in Q3 2022.
• Historically, Research & Development has averaged $15.9 million across 5 years, with a median of $14.8 million in 2023.
• Annual changes were most pronounced in 2024 — Research & Development surged 80.77% — and 2025, when it plunged 57.6%.
• Lexicon Pharmaceuticals' Research & Development stood at $14.0 million in 2022, then advanced by 5.62% to $14.8 million in 2023, then soared by 80.77% to $26.7 million in 2024, then slumped by 57.6% to $11.3 million in 2025, then gained by 12.74% to $12.8 million in 2026.
• Business Quant data shows LXRX's Research & Development at $12.8 million in Q1 2026, $11.3 million in Q4 2025, and $18.8 million in Q3 2025.